185 related articles for article (PubMed ID: 6251761)
21. Angiotensin inhibitors for hypertension.
Gavras H; Gavras I; Brunner HR
Compr Ther; 1980 May; 6(5):14-8. PubMed ID: 6155240
[TBL] [Abstract][Full Text] [Related]
22. [Treatment of essential arterial hypertension of moderate severity with an orally active inhibitor of the angiotensin converting enzyme (Captopril)].
Guerrera G; Melina D
Minerva Cardioangiol; 1983 Mar; 31(3):101-6. PubMed ID: 6304570
[No Abstract] [Full Text] [Related]
23. [Long term treatment of resistant hypertension with captopril (author's transl)].
Guedon J; Chaignon M; Lucsko M; Cuche JL; Aubert P; Piete AM
Nouv Presse Med; 1981 Apr; 10(19):1565-9. PubMed ID: 7025846
[TBL] [Abstract][Full Text] [Related]
24. [Evaluation of the acute effect of a converting enzyme inhibitor, captopril, in normal and hypertensive subjects].
Mimran A; Laroche B; Targhetta R; Roumieux JL
Arch Mal Coeur Vaiss; 1981 Jun; 74 Spec No():61-5. PubMed ID: 6794529
[TBL] [Abstract][Full Text] [Related]
25. Antihypertensive action of a novel orally active angiotensin converting enzyme inhibitor altiopril calcium (MC-838) in several hypertensive models of rats: comparison with captopril.
Aono J; Koga T; Yamazaki T; Shiraki Y; Sakai K
Arch Int Pharmacodyn Ther; 1988; 292():203-22. PubMed ID: 3293542
[TBL] [Abstract][Full Text] [Related]
26. [Effects of angiotensin I converting enzyme inhibitor (captopril) on blood pressure, pulse rate, plasma renin activity, and plasma aldosterone concentration in patients with essential hypertension and normal subjects].
Seto S; Kaku T; Shinagawa T; Matsumoto Y; Doi Y; Tasaki S; Murayama M; Aoi W; Kuramochi M; Hashiba K
Nihon Naika Gakkai Zasshi; 1980 Nov; 69(11):1439-46. PubMed ID: 7017040
[No Abstract] [Full Text] [Related]
27. [Acute inhibition of angiotensin-converting enzyme by captopril. Hemodynamic and biochemical aspects in normotension and essential hypertension].
Stanek B; Templ H; Pohanka E; Silberbauer K
Acta Med Austriaca; 1982; 9(5-6):175-80. PubMed ID: 6299046
[No Abstract] [Full Text] [Related]
28. [Angiotensin converting enzyme--captopril].
Kaneko Y; Shionoiri H; Uneda S; Fujishima S
Nihon Rinsho; 1979 Oct; 37(10):3492-8. PubMed ID: 392136
[No Abstract] [Full Text] [Related]
29. Converting enzyme inhibition with an orally active compound in hypertensive man.
Bravo EL; Tarazi RC
Hypertension; 1979; 1(1):39-46. PubMed ID: 232490
[TBL] [Abstract][Full Text] [Related]
30. Long-term efficacy of angiotensin-converting-enzyme inhibition with captopril in mild-to-moderate essential hypertension.
Stumpe KO; Overlack A; Kolloch R; Schreyer S
Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):121S-126S. PubMed ID: 6291563
[TBL] [Abstract][Full Text] [Related]
31. Hemodynamic and antihypertensive effects of captopril, an orally active angiotensin converting enzyme inhibitor.
Sullivan JM; Ginsburg BA; Ratts TE; Johnson JG; Barton BR; Kraus DH; McKinstry DN; Muirhead EE
Hypertension; 1979; 1(4):397-401. PubMed ID: 232084
[TBL] [Abstract][Full Text] [Related]
32. In vivo comparison of the renin inhibitor H77 with the angiotensin-converting enzyme inhibitor captopril.
Oldham AA; Arnstein MJ; Major JS; Clough DP
J Cardiovasc Pharmacol; 1984; 6(4):672-7. PubMed ID: 6206324
[TBL] [Abstract][Full Text] [Related]
33. Essential hypertension: effect of an oral inhibitor of angiotensin-converting enzyme.
MacGregor GA; Markandu ND; Roulston JE; Jones JC
Br Med J; 1979 Nov; 2(6198):1106-9. PubMed ID: 229941
[TBL] [Abstract][Full Text] [Related]
34. Effect of the angiotensin converting enzyme inhibitor, captopril (SQ14,225), on orthostatic sodium and water retention in patients with idiopathic edema.
Suzuki H; Fujimaki M; Nakane H; Saito I; Takeshita E; Saruta T
Nephron; 1985; 39(3):244-9. PubMed ID: 2983253
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of the chronotropic property of captopril in hypertensive patients.
Imai Y; Abe K; Sato M; Haruyama T; Hiwatari M; Goto T; Sato K; Kasai Y; Tajima J; Yoshinaga K
Am Heart J; 1982 Dec; 104(6):1339-45. PubMed ID: 6128916
[TBL] [Abstract][Full Text] [Related]
36. Effects of the angiotensin converting enzyme inhibitor, captopril, in essential hypertension.
Campbell BC; Shepherd AN; Reid JL
Br J Clin Pharmacol; 1982 Feb; 13(2):213-7. PubMed ID: 6277356
[TBL] [Abstract][Full Text] [Related]
37. Long-term captopril treatment in moderate to severe hypertension.
Santucci A; Aguglia F; De Mattia G; Ficara C; Balsano F
Br J Clin Pharmacol; 1982; 14 Suppl 2(Suppl 2):77S-79S. PubMed ID: 6753908
[TBL] [Abstract][Full Text] [Related]
38. Captopril: an oral angiotension converting enzyme inhibitor active in man.
Brunner HR; Gavras H; Waeber B; Turini GA; Wauters JP
Arch Int Pharmacodyn Ther; 1980; Suppl():188-212. PubMed ID: 6251762
[No Abstract] [Full Text] [Related]
39. Acute and chronic treatment of severe and malignant hypertension with the oral angiotensin-converting enzyme inhibitor captopril.
Case DB; Atlas SA; Sullivan PA; Laragh JH
Circulation; 1981 Oct; 64(4):765-71. PubMed ID: 6168412
[TBL] [Abstract][Full Text] [Related]
40. Captopril in mild and moderate essential hypertension: physiological and biochemical monitoring.
Rasmussen S; Leth A; Ibsen H; Damkjaer Nielsen M; Nielsen F; Giese J
Acta Med Scand Suppl; 1983; 677():105-9. PubMed ID: 6322529
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
